Vincristine chemical structure
Find information on thousands of medical conditions and prescription drugs.

Vincristine

Vincristine (OncovinĀ®) is an alkaloid from the Madagascar periwinkle (Catharanthus roseus, formerly Vinca rosea and hence its name). It is used in chemotherapy. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
Hydrocodone
Vagifem
Valaciclovir
Valcyte
Valganciclovir
Valine
Valium
Valnoctamide
Valproate semisodium
Valproic acid
Valpromide
Valrelease
Valsartan
Valstar
Valtrex
Vancenase
Vanceril
Vancomycin
Vaniqa
Vanticon
Vecuronium bromide
Velcade
Velivet
Venlafaxine
Ventolin
Vepesid
Verapamil
Verelan
Vermox
Versed
Vfend
Viadur
Viagra
Vicoprofen
Vidarabine
Vidaza
Videx
Vigabatrin
Viloxazine
Vinblastine
Vincristine
Vinorelbine
Viomycin
Vioxx
Viracept
Viread
Visine
Vistide
Visudyne
Vitaped
Vitrase
Vivelle
Volmax
Voltaren
Voriconazole
Vosol
W
X
Y
Z

Mode of action

Tubulin is a structural protein which polymerises to form microtubules. The cell cytoskeleton and mitotic spindle, amongst other things, are made of microtubules. Vincristine binds to tubulin dimers causing disassembly of microtubule structures. Disruption of the microtubules arrests mitosis in metaphase. The vinca alkaloids therefore affect all rapidly dividing cell types, including cancer cells but also as intestinal epithelium and bone marrow.

Side effects

The main side-effects of vincristine are peripheral neuropathy and constipation. The latter may require laxatives, while the former can be a reason to reduce the dose of vincristine.

Accidental injection of vinca alkaloids into the spinal canal (intrathecal administration) is highly dangerous, with a mortality rate approaching 100%. The medical literature documents cases of ascending paralysis due to massive encephalopathy and spinal nerve demyelination, accompanied by intractable pain, almost uniformly leading to death; a handful of survivors were left with devastating neurological damage with no hope of recovery.

Uses

Vincristine, injected intravenously only, is used in various types of chemotherapy regimens. Its main uses are in non Hodgkin's lymphoma as part of the chemotherapy regimen CHOP, Hodgkin's lymphoma as part of the Stanford V chemotherapy regimen, and in acute lymphoblastic leukemia.

History

Having been used as a folk remedy for centuries, studies in the 1950s revealed that C. roseus contained 70 alkaloids, many of which biologically active. Vincristine gained FDA approval in July 1963 as Oncovin. The drug was initially marketed by Eli Lilly.

Suppliers

Three generic drug makers supply vincristine in the United States - APP, Mayne, and Sicor.

Read more at Wikipedia.org


[List your site here Free!]


Myelomatous pleural effusion and airway compression complicating multiple myeloma
From CHEST, 10/1/05 by Steven M. Rowe

INTRODUCTION: Myelomatous pleural effusion is a very rare manifestation of multiple myeloma, and represents the small minority of pleural effusions associated with this disorder. Pleural myeloma has also rarely been associated with mediastinal involvement of malignant plasma cells. We report a case of pleural myeloma associated with mediastinal disease and extrinsic compression of the airway.

CASE PRESENTATION: A 72 year-old white male with a history of coronary artery disease, hypertension, and multiple myeloma was in his usual state of health until eight weeks prior when he developed slowly progressive dyspnea, orthopnea, and wheezing. He denied fever, chills, cough, or chest pain. Four weeks prior he was hospitalized for pneumonia and anemia, and treated with levofloxacin, corticosteroids, and packed red cell transfusions. He had an initial clinical improvement, however, three weeks prior to admission his symptoms recurred despite compliance with his medical regimen. Medical history included multiple myeloma (IgA lambda) diagnosed 4 months prior and treated initially with doxorubicin, prednisone, and vincristine; coronary artery disease status post bypass grafting; hypertension; and diastolic dysfunction. Medications included thalidomide, metoprolol, furosemide, and erythropoietin. Social history was notable for previous tobacco use. Physical exam revealed a chronically ill appearing man who was in no acute distress. Respirations were unlabored and his oxygen saturation was 92% on room air. Brea-th sounds were decreased on the right with dullness to percussion and decreased tactile fremitus. Wheezing was also noted intermittently. Cardiac exam was unremarkable. Initial laboratory exam revealed a WBC 1.3k, Hemoglobin of 7.9 g/dL, and platelets of 32k. Chest radiograph showed a right pleural effusion that had increased in size on serial films. Non-contrast CT of the chest revealed a large loculated right pleural effusion with associated lower lobe atelectasis, and extrinsic compression of the trachea (Figure 1). Ultrasound guided thoracentesis revealed bloody fluid, with WBC 1.5K (differential 88% plasma cells and 6% neutrophils), an LDH of 221 U/L (80% of serum value), a protein of 7.4 g/dL (68% of serum), and glucose of 157 mg/dL. Due to the possibility of airway compression and the atypical pleural effusion, the patient underwent bronchoscopic airway inspection and video assisted thorascopic surgery. Findings included mild external compression of the trachea, and firm, round nodules throughout the pleural surface. Tumor was debulked and talc pleurodesis was performed. Pathology revealed atypical plasma cells consistent with myeloma (Figure 2). Due to the failure of previous chemotherapy regimen, the patient elected to forgo additional treatments and received palliative care. He expired at home 6 weeks later.

[FIGURES 1-2 OMITTED]

DISCUSSIONS: Multiple myeloma is a neoplastic disorder caused by the proliferation of a single plasma cell clone, and is associated with the production of monoclonal immunoglobulin. Pleural effusions occur in approximately 6% of patients with myeloma due to a variety of causes; however, myelomatous pleural involvement occurs in less than 1% of cases. Mediastinal involvement is also quite rare, and may be the source of pleural disease. As in this case, the majority of myelomatous effusions are due to those that produce IgA, as this type tends to invade extraosseous structures. Diagnosis requires immunoelectrophoresis of the pleural fluid or histologic confirmation. Treatment is directed at the underlying disease, but may also include pleurodesis for symptomatic control and appropriate airway management.

CONCLUSION: Myelomatous pleural effusion with mediastinal involvement is a rare manifestation of multiple myeloma, and may mimic infectious complications of the disease. This entity should be considered in those with advanced disease.

REFERENCES:

(1) MG Alexandrakis, FH Passam, DS Kyriakou, D Bouros. Pleural Effusions in Hematologic Malignancies. Chest 2004; 125:1546-52.

(2) JS Kintzer, EC Rosenow, RA Kyle. Thoracic and pulmonary abnormalities in multiple myeloma. Arch Intern Med 1978; 138:727-73.

DISCLOSURE: Steven Rowe, None.

Steven M. Rowe MD * University of Alabama at Birmingham, Birmingham, AL

COPYRIGHT 2005 American College of Chest Physicians
COPYRIGHT 2005 Gale Group

Return to Vincristine
Home Contact Resources Exchange Links ebay